Experiences with
Acalabrutinib568 public posts
Want to take advantage of all our features? Just log in!
or
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Estimated 36-month overall survival was 94.1% with acalabrutinib–venetoclax, 87.7% with acalabrutinib–venetoclax–obinutuzumab, and 85.9% with chemoimmunotherapy.
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
[i][/i]
[i]Patients were divided into 3 groups:[/i]
[i] 1) acalabrutinib alone[/i]
[i] 2) acalabrutinib plus obinutuzumab, a monoclonal antibody[/i]
[i]3) the usual chemoimmunotherapy treatment (chlorambucil plus a monoclonal antibody).
New Greek consensus statement for the treatment of chronic lymphocytic leukemia
No significant difference was seen in terms of PFS between Ibrutinib monotherapy and Ibrutinib - Rituximab in the ALLIANCE trial.¹⁵ In the ELEVATE TN trial, at 6 years of follow-up, PFS was significantly longer in patients treated with Acalabrutinib plus Obinutuzumab versus Acalabrutinib, while
Why does ibrutinib cause nail brittleness (onychorrhexis and onychoschizia) or curly hair in some CLL patients? What can you do about it?
/efficacy-and-safety-of-new%E2%80%91generation-btkis-primarily-acalabrutinib-and-zanubrutinib-in-cll-sll-a-systematic-review-and-meta%E2%80%91analysis[/i]
[i]Largest real world study of and ibrutinib over 3 years, shows acalabrutinib has improved discontinuation rates[/i]
[i]https